taniborbactam [Adjuvant]

Download Sequences

Accession ARO:3007147
DefinitionTaniborbactam is a broad-spectrum beta-lactamase inhibitor. As of 2022, it is in phase III clinical trials in combination with cefepime and is the only beta-lactamase inhibitor exhibiting activity against all four classes of beta-lactamase.
Classification6 ontology terms | Show
Parent Term(s)11 ontology terms | Show
+ boronic acid beta-lactamase inhibitor
+ is_small_molecule_inhibitor CMY-2
+ is_small_molecule_inhibitor CTX-M-15
+ is_small_molecule_inhibitor IMP-1
+ is_small_molecule_inhibitor KPC-2
+ is_small_molecule_inhibitor NDM-2
+ is_small_molecule_inhibitor OXA-1
+ is_small_molecule_inhibitor OXA-48
+ is_small_molecule_inhibitor SHV-5
+ is_small_molecule_inhibitor VIM-2
+ unclassified metallo-beta-lactamase inhibitor
1 ontology terms | Show
+ cefepime-taniborbactam [Antibiotic+Adjuvant] has_part

Hamrick JC, et al. 2020. Antimicrob Agents Chemother 64(3): VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. (PMID 31871094)